Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001972593 | SCV002242726 | pathogenic | Anophthalmia/microphthalmia-esophageal atresia syndrome | 2021-06-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SOX2 protein in which other variant(s) (p.Pro181Argfs*22) have been determined to be pathogenic (PMID: 22171155). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This sequence change creates a premature translational stop signal (p.Tyr180Glyfs*25) in the SOX2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 138 amino acid(s) of the SOX2 protein. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with SOX2-related conditions. |